Research programme: antiviral vaccines - Profectus BioSciences

Drug Profile

Research programme: antiviral vaccines - Profectus BioSciences

Alternative Names: Chikungunya virus vaccine - Profectus; filovirus MCM - Profectus; HCV vaccine - Profectus BioSciences; HPV vaccine - Profectus BioSciences; HSV vaccine - Profectus BioSciences; Lassa fever vaccine - Profectus; Preventative HIV rVSV vaccine - Profectus; rVSV Marburg vaccine; rVSV-Ebola vaccine - Profectus; rVSVN4CT1 Z Ebola; VesiculoVax rVSV-vectored Ebola/Marburg vaccine; VesiculoVax™-EEEV; VesiculoVax™-VEEV; Z EboV rVSVN4CT1

Latest Information Update: 23 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Profectus Biosciences
  • Developer Profectus Biosciences; University of Texas Medical Branch
  • Class AIDS vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Marburg virus disease; Venezuelan equine encephalomyelitis; Viral infections; Zika virus infection
  • Research Lassa fever

Most Recent Events

  • 16 Aug 2018 Emergent BioSolutions has exclusive option to license the development activities of Lassa virus vaccine from Profectus
  • 02 Oct 2017 Profectus BioSciences plans a phase I trial for the treatment of Ebola, Marburg, and Lassa virus infections
  • 20 Jan 2017 Preclinical development is ongoing in Marburg virus disease(Prevention) in USA (IM, Injection) (Profectus Biosciences pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top